Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.
The primary use of menopausal hormone therapy (MHT) is to alleviate symptoms of oestrogen deficiency, such as hot flushes, night sweats, sleep disturbance, arthralgia and vulvovaginal atrophy symptoms.1 Co-prescription of a progestogen is essential with oestrogen therapy for perimenopausal or postmenopausal women with an intact uterus to protect against endometrial hyperplasia and the possibility of endometrial carcinoma. The progestogen is usually administered cyclically for 14 days per month up until 12 months after the final menstrual period, resulting in cyclical menstrual loss. After that, the progestogen may be taken continuously, such that menstrual bleeding does not occur.
Picture credit: © Lilliday/iStockphoto.com. Model used for illustrative purposes only.